Navigation Links
Researchers seek to make cavity-causing bacteria self-destruct
Date:1/2/2008

Bacteria that eat sugar and release cavity-causing acid onto teeth may soon be made dramatically more vulnerable to their own acid. Researchers have identified key genes and proteins that, if interfered with, can take away the ability of a key bacterial species to thrive as its acidic waste builds up in the mouth.

The ability of Streptococcus mutans (S. mutans) to survive in acid is one reason that the species is the main driver of tooth decay worldwide. Past research has shown that this ability has several components including a bacterial enzyme called fatty acid biosynthase M (FabM), which when shut down, makes S. mutans almost precisely 10,000 times more vulnerable to acid damage.

In addition, early work suggests that FabM or one of its relatives may also help all Streptococci (strep) and Staphylococci (staph) infections to resist the human bodys defenses, which include immune cells that subject bacteria to acid. Between them, strep and staph bacteria are responsible for meningitis, pneumonia, sepsis, methicillin-resistant staph aureus, the flesh-eating infection (fasciitis), as well as infections on heart valves and around stents.

While FabM represents a major target for the design of new drugs, the focus of the next round of work is to identify and rank every one of the 2,000 known S. mutans genes that contributes to its fitness (ability to survive, out-compete other strains and cause disease). A research team at the University of Rochester Medical Center today announced that it has received a $3.6 million fitness profiling grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). Grant-funded projects will seek to create a catalogue of proteins that, along with FabM, can serve as targets for a multi-pronged attack on bacteria that tend to evolve around single-thrust treatments.

Our first goal is to force the major bacterium behind tooth decay to destr
'/>"/>

Contact: Greg Williams
Greg_Williams@urmc.rochester.edu
University of Rochester Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...ocus on Millions of Children Still in Danger, NEW...ICEF and The,Advertising Council today announced a... national public service announcements (PSAs) film...icole Ritchie, Joel Madden, David,Duchovny, Tea Le... of the,Myanmar cyclone. The Ad Council is distrib...
(Date:5/16/2008)...PRNewswire/ -- ExamForce announced today the,hirin...nment Sales Manager.,Mongeon formerly headed up th... where he oversaw government sales and marketing i...p security certifications in the IT,industry., Mo... left (ISC)2,Americas to spend more time with his ...
(Date:5/16/2008)...kly disseminated to community physicians, audit fi...-- Partnerships between major academic cancer cent...ive way to spread cancer treatment advances, say r...hia. , Most new cancer treatments are created a...rovided at community hospitals, noted the research...
(Date:5/16/2008)... /PRNewswire-USNewswire/ -- Karin Weisburgh,senio...it publisher of,Consumer Reports magazine, was nam...r at CU,s Yonkers headquarters today., Ms. Weisbu...dles up in,the winter and rides in shirt sleeves i...long Quaker Ridge in New Rochelle, down Mill Road ...
Breaking Medicine News(10 mins):Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 2Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 3Health News:Partnerships Effective Communicators of Cancer Advances 2Health News:Westchester Cycle Club Awards Consumers Union Staffer Karin Weisburgh Commuter of the Year 2Health News:Westchester Cycle Club Awards Consumers Union Staffer Karin Weisburgh Commuter of the Year 3
... the latest issue of Current Directions in Psychol...s with out us even knowing of it//. The article ex...ther people do and how they express their feelings.... Explaining that the stirring in the back of our...
...itoba are facing public ire for not acting quickly...ed in northern Manitoba First Nations communities....en diagnosed with the condition in and around the ...ident of Garden Hill told CBC News that he became ...
...ascinate by "goths" — a group fascinated by the da... self harm and suicide attempts.// University of...n 1,258 young adults several times throughout thei... of teens who said they were goths admitted to sel...
...drug to treat alcoholism by taking it just once a ...e drug, // Vivitrol, an injectable form of naltrex...for alcohol. ReVia by Barr Pharmaceuticals Inc. i... generically. This drug would be freely available ...
Other Medicine News:
(Date:5/15/2008)...wswire/ -- Patients with breast or,colorectal canc...pect,further treatment advances with Avastin(R) (b...ng new data that is being presented at the 44th,Am...meeting in Chicago at,the end of May. Around 30,00... the premier event for cancer therapy worldwide., ...
(Date:5/15/2008)... from Prostate, Colorectal and Ovarian ...nvestor Event on Sun., June 1 with Oncology Expert...ire-FirstCall/ -- Poniard,Pharmaceuticals, Inc. (N...d,on oncology, today announced that the Company wi...platin, in various tumor types and combinations, a...
(Date:5/15/2008)...arch reflects depth and breadth of, collaboration...ments for diverse forms of ...Zometa(R), the leading IV, bisphosphonate, on rela...r, - Four oral sessions to feature RAD001, first ...luding first results of RECORD-1 study in renal ce...
(Date:5/15/2008)...swire-FirstCall/ -- Sanofi-aventis,(EURONEXT: SAN ...the,landmark ATHENA study showed Multaq(R) (droned...atients with atrial fibrillation or atrial flutter...tions or death from any,cause by a statistically s...rimary endpoint. The ATHENA results will be presen...
Breaking Medicine Technology:New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Ketamine Impairs Brain by Releasing Superoxide 7775 1Ketamine Impairs Brain by Releasing Superoxide 7775 2St Jude finds mechanism for faulty protein disposal 7771 1St Jude finds mechanism for faulty protein disposal 7771 2St Jude finds mechanism for faulty protein disposal 7771 3St Jude finds mechanism for faulty protein disposal 7771 4Blackberries Broccoli Sprouts Battle Cancer 7769 1Blackberries Broccoli Sprouts Battle Cancer 7769 2Blackberries Broccoli Sprouts Battle Cancer 7769 3Blackberries Broccoli Sprouts Battle Cancer 7769 4Construction Begins on Los Angeles First New Continuing Care Retirement Community Facility in Over a Decade 7766 1Construction Begins on Los Angeles First New Continuing Care Retirement Community Facility in Over a Decade 7766 2
...erides and cholesterols, vary with genetic predisp...f these factors contribute to serum cholesterol an...sk of untoward vascular and cardiac events. Perhap...values are so much in the public eye as serum leve... discussion of plasma lipid test results an opport...
...cessary to plan or evaluate anticoagulant therapy,... hyperhomocystinemia, elevated factor VIII levels,...rders of plasmin generation, and to assess acquire...te, antiphospholipid syndrome, hyperhomocystinemia...red along with other tests (such as aspirate amino...
Other Medicine Technology:Analyzers Offer Point-of-Care Lipid Panels 2Analyzers Offer Point-of-Care Lipid Panels 3Prothrombin Time Comes in Small (CLIA-Waived) Packages 2Prothrombin Time Comes in Small (CLIA-Waived) Packages 3
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
...atory and a worldwide leader in innovative laborat...sive test menu of highly complex and unique medica...by the University of Utah, ARUP Laboratories' clie...ity teaching hospitals and children's hospitals, m...
Medicine Products: